Showing results (131-140 of 145) with videos related to
Sort By:
Pageof 15
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.Brain : a Journal of Neurology|January 25, 2015
Genetic variants are major determinants of CSF antibody levels in multiple sclerosisAn Goris, Ine Pauwels, Marte W Gustavsen, et al.Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.NPJ Digital Medicine|July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical dataAshkan Pirmani, Edward De Brouwer, Ádám Arany, et al.Annals of Neurology|December 23, 2011
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility lociNikolaos A Patsopoulos, , , et al.Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.Pageof 15